Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment

Risultato della ricerca: Contributo in rivistaArticolo in rivista

22 Citazioni (Scopus)

Abstract

Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome is a rare disease which is often misdiagnosed and under-recognized, because of its peculiar and heterogeneous clinical presentation. Its main features consist of cutaneous and osteoarticular manifestations, the latter affecting more often the anterior chest wall and having typical radiologic findings. There are no validated diagnostic criteria for SAPHO and no guidelines for treatment, due mainly to its rarity; as a consequence, therapy is empirical and aimed to control pain and modifying inflammatory process. To date, the use of anti-TNF agents has been proved to be a valid alternative for patients unresponsive to conventional treatments, such as NSAIDs, corticosteroids, DMARDs and biphosphonates. The clinical heterogeneity of the disease, possibly due to differences in pathogenic mechanism of different manifestations, is challenging for both diagnosis and treatment, which should aim to control both skin and bone involvement in different clinical subsets. Here, we summarize the current status of knowledge about the SAPHO syndrome and present two cases of patients with very different disease manifestations, suggesting the need for personalized treatment.
Lingua originaleEnglish
pagine (da-a)2151-2158
Numero di pagine8
RivistaCLINICAL RHEUMATOLOGY
Volume36
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • Acquired Hyperostosis Syndrome
  • Adrenal Cortex Hormones
  • Anti-Inflammatory Agents, Non-Steroidal
  • Biologic drugs
  • Diphosphonates
  • Female
  • Humans
  • Hyperostosis
  • Middle Aged
  • Osteitis
  • Pain
  • Pain Management
  • SAPHO
  • Skin
  • Skin Diseases
  • Treatment
  • Tumor Necrosis Factor-alpha

Fingerprint Entra nei temi di ricerca di 'Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment'. Insieme formano una fingerprint unica.

Cita questo